This is an automatically translated article.
Cataflam 25mg drug is used to treat chronic arthritis and some short-term symptoms such as acute exacerbations of paraarticular inflammation, gouty arthritis.
1. What is Cataflam 25mg?
Cataflam's main ingredient is Diclofenac potassium, which belongs to the group of pain relievers, is prepared in the form of sugar coated tablets with a content of 25 mg, manufactured by Interpharma Manufacturing Co., Ltd.Cataflam 25 mg drug is prescribed by doctors to use in the following cases:
Treatment of post-traumatic pain, inflammation and swelling caused by sprains. Relieve pain after surgery or minor surgery, especially inflammation and swelling such as after orthopedic or dental surgery. Improve pain or inflammation in Gynecology such as adnexitis or primary dysmenorrhea. Acute musculoskeletal disorders and trauma such as periarthritis (especially frozen shoulder), tendinitis, tenosynovitis, bursitis, sprains, strains and dislocations. Migraine pain relief Spine pain syndrome Rheumatoid arthritis, osteoarthritis Adjuvant treatment in infections that cause severe pain in the nose, ears or throat such as tonsillitis, pharyngitis, otitis .
2. What are the uses of Cataflam 25mg?
2.1 Pharmacodynamics Cataflam sugar coated tablets contain the potassium salt of diclofenac, a nonsteroidal compound with clinically proven analgesic, anti-inflammatory and antipyretic properties.
The mechanism of action of diclofenac potassium tablets, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. The diclofenac concentrations achieved during treatment produced effects in vivo. Prostaglandins sensitize afferent nerves and enhance bradykinin activity in pain induction in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to the reduction of prostaglandins in peripheral tissues.
Cataflam tablets have a rapid onset of action and are therefore suitable for the treatment of acute episodes of pain and inflammation.
During migraine attacks, Cataflam sugar coated tablets have been shown to be effective in reducing headaches and improving associated nausea.
Diclofenac in vitro did not prevent proteoglycan biosynthesis in cartilage at concentrations comparable to those achieved in humans.
2.2. Pharmacokinetic properties Absorption:
Diclofenac is rapidly and completely absorbed from the sugar coated tablet. Food intake does not affect the absorption of the drug. Peak plasma concentrations following a 50 mg sugar coated tablet are 3.9 μmol/l after 20-60 minutes. Plasma concentrations show a linear relationship with the size of the dose. Diclofenac undergoes first-pass metabolism and is extensively metabolized. Distribution:
Diclofenac is highly bound to plasma proteins (99.7%), mainly to albumin (99.4%) Diclofenac was detected at low concentrations (100ng/mL) in breast milk in a nursing mother. Breastfeeding. The estimated amount ingested by a breastfed infant is equivalent to a dose of 0.03 mg/kg/day. Elimination:
The systemic clearance of diclofenac in plasma is 263 ± 56 ml/min (mean ± SD). The terminal plasma half-life is 1-2 hours. Repeated oral administration of Diclofenac Potassium Tablets for 8 days at a daily dose of 50 mg tds did not lead to accumulation of diclofenac in plasma. Approximately 60% of the administered dose is excreted in the urine as metabolites, and less than 1% as unchanged drug. The remainder of the dose is eliminated as bile metabolites in the faeces.
3. Contraindications of Cataflam 25mg
Patients with hypersensitivity to the active substance or to any of the excipients of the drug Cataflam 25 mg Patients with gastric or intestinal ulcers/perforation The last trimester of pregnancy Patients with severe liver or kidney failure (glomerular filtration rate GFR) <15ml/min/1.73m2) Patients with congestive heart failure (from grade II to grade IV according to the functional classification of heart failure according to the New York Heart Association - NYHA), peripheral artery disease, ischemic heart disease Local, cerebrovascular disease Patients with asthma attacks, urticaria or acute rhinitis caused by acetylsalicylic acid or other NSAIDs History of gastrointestinal bleeding or gastrointestinal perforation related to treatment with NSAIDs.
4. Side effects when using Cataflam 25 mg
Central nervous system side effects:
Uncommon: Dizziness, dizziness, headache Rare: Drowsiness Very rare: Tremor, restlessness, depression, convulsions, insomnia, mental confusion memory, sensory disturbances, convulsions,... Side effects on digestive organs:
Uncommon: Nausea, epigastric pain, abdominal distension, anorexia, intestinal spasms, diarrhea Rare: Stomach ulcers Gastroenteritis, gastrointestinal bleeding Very rare: Glossitis, oral mucositis, constipation, pancreatitis, Crohn's disease, nonspecific hemorrhagic colitis, histological stenosis,... Skin side effects :
Uncommon: Skin rash, urticaria rash Rare: Eczema, Steven-Johnson syndrome, vesicular rash, erythema multiforme, exfoliative dermatitis, Lyell's syndrome, alopecia, hemorrhage allergies, purpura and photosensitivity. Sensory side effects:
Hearing loss Taste disturbance Visual disturbances (double vision, blurred vision) Sensory side effects are very rare when using Cataflam. Renal side effects (rare):
Edema Acute renal failure Renal papillary necrosis Nephrotic syndrome Interstitial nephritis Liver side effects:
Fulminant hepatitis Hepatitis with/without jaundice Increased blood aminotransferases Other side effects:
Leukopenia Aplastic anemia Thrombocytopenia Agranulocytosis Hypersensitivity (pneumonia, vasculitis, asthma) High blood pressure Congestive heart failure Palpitations
5. Drug interactions
Lithium: If used concomitantly, Cataflam may increase plasma lithium concentrations. Serum lithium levels should be monitored. Digoxin: If administered concomitantly, Cataflam may increase plasma digoxin concentrations. Monitoring of serum digoxin levels is recommended. Diuretics and antihypertensives: As with other NSAIDs, concomitant use of diclofenac with diuretics and antihypertensives (eg, beta-blockers, ACE inhibitors) may reduce the effect of diuretics and antihypertensives. antihypertensive effect due to inhibition of vasodilator prostaglandin synthesis). Therefore, the combination of drugs should be cautious and patients, especially the elderly, should have their blood pressure monitored periodically. Patients should be adequately hydrated and renal function monitoring should be considered after initiation of concomitant therapy at regular intervals thereafter, particularly with diuretics and ACE inhibitors due to the increased risk of toxicity. kidney. Drugs Known to Cause Hyperkalemia: Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may increase serum potassium levels and therefore should be monitored frequently. Anticoagulants and antiplatelet agents: Caution should be exercised because concomitant use may increase the risk of bleeding. Although clinical studies have not shown that diclofenac affects the effects of anticoagulants, an increased risk of bleeding has been reported in patients receiving concomitant Cataflam and anticoagulants. Therefore, to ensure that the dose of anticoagulants does not change, it is necessary to closely monitor such patients. As with other non-steroidal anti-inflammatory drugs, diclofenac at high doses can reverse platelet aggregation. Other NSAIDs including selective cyclooxygenase-2 inhibitors and corticosteroids: Concomitant administration of Cataflam with other systemic NSAIDs or corticosteroids may increase the risk of gastrointestinal ulceration or bleeding. Concomitant use of two or more NSAIDs Selective serotonin reuptake inhibitors (SSRIs) should therefore be avoided: Concomitant use of SSRIs may increase the risk of gastrointestinal bleeding. Antidiabetic agents: Clinical studies have shown that diclofenac can be used with oral antidiabetic agents without affecting the clinical effects of the drug. However, there have been separate reports of hypoglycaemic and hyperglycemic effects that necessitated a change in the dose of the antidiabetic agent during treatment with Cataflam. For this reason, blood glucose levels should be monitored as a precaution during concomitant therapy. Methotrexate: Cataflam may inhibit the tubular clearance of methotrexate thereby increasing methotrexate concentrations. Caution should be exercised when NSAIDs, including diclofenac, are used less than 24 hours prior to methotrexate therapy. Ciclosporin: The diclofenac in Cataflam, like other NSAIDs, may increase the nephrotoxicity of cyclosporin by acting on renal prostaglandins. Therefore, a lower dose should be used for patients not receiving ciclosporin. Tacrolimus: There may be an increased risk of nephrotoxicity when NSAIDs are taken with tacrolimus. This may be mediated through the renal anti-prostaglandin effects of both NSAIDs and calcineurin inhibitors. Quinolone antibodies: Convulsions may occur due to interactions between quinolones and NSAIDs. This may occur in patients with or without a prior history of seizures or convulsions. Therefore, caution should be exercised when considering the use of quinolones in patients receiving NSAID therapy. Phenytoin: When phenytoin is co-administered with Cataflam, plasma concentrations of phenytoin should be monitored because of the expected increase in phenytoin exposure. Colestipol and cholestyramine: These agents may delay or decrease the absorption of Cataflam. Therefore, Cataflam should be taken at least one hour before or 4 to 6 hours after colestipol/cholestyramine. Cardiac Glycosides: Concomitant use of cardiac glycosides and Cataflam in patients may worsen heart failure, increase plasma glycosides, and decrease GFR. Mifepristone: NSAIDs should not be used for 8-12 days after taking mifepristone because these drugs may decrease the effect of mifepristone. Strong CYP2C9 Inhibitors: Caution is advised when co-prescribing Cataflam with strong CYP2C9 inhibitors (e.g. voriconazole), which can significantly increase peak plasma concentrations and diclofenac exposure by inhibiting metabolism. diclofenac . Zidovudine: Increased risk of hematologic toxicity when NSAIDs are used with zidovudine. There is evidence of an increased risk of coagulopathy and hematoma in HIV (+) hemophilia treated concomitantly with zidovudine and ibuprofen.
6. Precautions when using Cataflam 25mg
Cataflam is usually not harmful if used in the right dose for a short period of time. However, in patients with a history of peptic ulcer, liver failure or Crohn's disease, close monitoring is necessary to avoid the risk of gastrointestinal bleeding. Cataflam is metabolised by the liver and may cause abnormal elevations of liver enzymes. In addition, Cataflam dysmenorrhea can also trigger flare-ups in patients with hepatic porphyria. Care should be taken when using the drug in the elderly, patients with heart failure and kidney failure. In addition, Cataflam has antiplatelet properties, so caution should be used in patients with coagulopathy. Cataflam can relieve symptoms of infection (fever, pain and inflammation). Therefore, in cases of suspected pelvic pain due to pelvic inflammatory disease, it is necessary to conduct a medical examination before use. If you notice signs of gastrointestinal bleeding, stomach perforation (vomiting coffee-colored liquid, bloody stools, severe epigastric pain), you should stop taking the drug and go to the hospital as soon as possible. Concomitant use of Cataflam with alcohol may increase the risk of stomach ulcers and gastrointestinal bleeding. In addition, while taking the drug, you need to limit foods that are harmful to the stomach such as carbonated soft drinks, sour, salty and hot spicy foods. Some patients may experience visual disturbances while taking the drug. In this case, it is necessary to limit the use of vehicles or operating machinery.
7. How to use Cataflam 25mg effectively?
How to use:
Cataflam is used orally. The drug can be taken during or after meals because clinical trials have shown that food does not reduce the extent to which the body absorbs the drug. However, in cases where the patient does not have stomach pain, the drug can be taken before meals so that the drug can work in the shortest time. Usual Adult Dose:
Initial daily dose 100-150mg/day Should be divided into 2 to 3 oral doses, 4 hours apart In case of mild pain or use For children over 14 years old:
Use 75-100mg/day Divided into 2 to 3 times a day Dosage in the treatment of primary dysmenorrhea:
Use 50-150mg/day For special cases, it can be used 200mg/day Should be divided into 3 times a day Dosage for migraine treatment:
First dose: 50mg/time After 2 hours if symptoms do not improve, can take another 50mg/time After that, continue 50mg for 4-6 hours Maximum dose: 200mg/24 hours In summary, Cataflam 25mg is used to treat chronic arthritis. Patients should carefully read the instructions for use, consult a doctor before use. Absolutely do not buy drugs on your own because there may be unwanted side effects.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
